Review
Oncology
Eunus S. Ali, Shamima Akter, Sarker Ramproshad, Banani Mondal, Thoufiqul Alam Riaz, Muhammad Torequl Islam, Ishaq N. Khan, Anca Oana Docea, Daniela Calina, Javad Sharifi-Rad, William C. Cho
Summary: The MAPK pathway plays a crucial role in transmitting signals from outside the cell to inside, and is associated with cancer treatment response, normal cell pathway maintenance, and compensatory pathway activation. MAPK inhibitors often activate compensatory feedback loops, leading to resistance in tumor cells and microenvironment. Therefore, innovative combination therapies are needed to limit alternate pathway initiation.
CANCER CELL INTERNATIONAL
(2022)
Review
Plant Sciences
Ressin Varghese, Thomas Efferth, Siva Ramamoorthy
Summary: Lung cancer, a leading malignancy worldwide, has been mitigated through the use of phytopigments such as carotenoids. While in vitro and animal studies have shown promising results, clinical trials have yielded contradictory outcomes, highlighting the need for further verification.
Article
Developmental Biology
Nanbing Li-Villarreal, Rebecca Lee Yean Wong, Monica D. Garcia, Ryan S. Udan, Ross A. Poche, Tara L. Rasmussen, Alexander M. Rhyner, Joshua D. Wythe, Mary E. Dickinson
Summary: This study reveals a novel role for FOXO1 as a key transcriptional repressor regulating both pre-flow arterial specification and subsequent vessel remodeling within the murine YS.
Article
Cell Biology
Rui Tang, Emily G. G. Shuldiner, Marcus Kelly, Christopher W. W. Murray, Jess D. D. Hebert, Laura Andrejka, Min K. K. Tsai, Nicholas W. W. Hughes, Mitchell I. I. Parker, Hongchen Cai, Yao-Cheng Li, Geoffrey M. M. Wahl, Roland L. L. Dunbrack, Peter K. K. Jackson, Dmitri A. A. Petrov, Monte M. M. Winslow
Summary: Using CRISPR/Cas9 technology, Tang et al. show that HRAS and NRAS suppress the growth of KRAS-driven lung cancer by inhibiting KRAS-KRAS interactions and reducing downstream ERK signaling. The study highlights the specific suppressive role of RAS paralogues in KRAS-driven lung cancer, as compared to BRAF-driven lung cancer.
NATURE CELL BIOLOGY
(2023)
Article
Cell Biology
Jeeho Kim, Young Jin Jeon, Sung-Chul Lim, Joohyun Ryu, Jung-Hee Lee, In-Youb Chang, Ho Jin You
Summary: Ephexin1 is highly expressed in patient tissues of colorectal cancer (CRC) and lung cancer (LC), and plays a critical role in promoting tumorigenesis through the Ras-mediated signaling pathway. Phosphorylated Ephexin1 at Ser16 and Ser18 (pSer16/18) may serve as an effective therapeutic target for CRC and LC as it interacts with oncogenic K-Ras to promote downstream MAPK signaling.
CELL DEATH & DISEASE
(2021)
Review
Oncology
R. L. Keith, Y. E. Miller, M. Ghosh, Wilbur A. Franklin, I. Nakachi, D. T. Merrick
Summary: Lung cancer progresses through pre-malignant histo-logic changes before becoming invasive, with genetic and epigenetic alterations, immune response, and microenvironmental factors contributing to the risk. Medical prevention studies have been conducted, and future trials will focus on precision chemoprevention based on the understanding of pre-malignancy.
SEMINARS IN ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Atish Mohanty, Arin Nam, Saumya Srivastava, Jeff Jones, Brett Lomenick, Sharad S. Singhal, Linlin Guo, Hyejin Cho, Aimin Li, Amita Behal, Tamara Mirzapoiazova, Erminia Massarelli, Marianna Koczywas, Leonidas D. Arvanitis, Tonya Walser, Victoria Villaflor, Stanley Hamilton, Isa Mambetsariev, Martin Sattler, Mohd W. Nasser, Maneesh Jain, Surinder K. Batra, Raffaella Soldi, Sunil Sharma, Marwan Fakih, Saswat Kumar Mohanty, Avijit Mainan, Xiwei Wu, Yihong Chen, Yanan He, Tsui-Fen Chou, Susmita Roy, John Orban, Prakash Kulkarni, Ravi Salgia
Summary: This study reveals non-genetic mechanisms of resistance to sotorasib and proposes a treatment strategy to enhance sensitivity by targeting both ITGB4 and beta-catenin.
Article
Cell Biology
Batel Shalom, Marganit Farago, Yaser Salaymeh, Shulamit Sebban, Matan Risling, Eli Pikarsky, Shulamit Katzav
Summary: Vav1 has a potential impact on lung cancer development and synergizes with K-Ras mutant gene to enhance tumor growth, while also regulating cytokine production, immune cell infiltration, and ERK phosphorylation in lung tumors.
CELLULAR SIGNALLING
(2022)
Article
Biochemistry & Molecular Biology
Dong Hoon Shin, Jeong Yeon Jo, Minyoung Choi, Kyung-Hee Kim, Young-Ki Bae, Sang Soo Kim
Summary: The interaction between SIRT1 and p300 in KRAS-mutant lung cancer cells plays a critical role in tumor progression, suggesting the potential use of SIRT1 inhibitors and p300 activators in combination therapy for KRAS-mutant lung cancer patients.
EXPERIMENTAL AND MOLECULAR MEDICINE
(2023)
Article
Cell Biology
Ja-Yeol Lee, Jung-Won Lee, Tae-Geun Park, Sang-Hyun Han, Seo-Yeong Yoo, Kyoung-Mi Jung, Da-Mi Kim, Ok-Jun Lee, Dohun Kim, Xin-Zi Chi, Eung-Gook Kim, You-Soub Lee, Suk-Chul Bae
Summary: This study provides in vivo evidence supporting RUNX3 as a therapeutic tool for the treatment of K-RAS-activated lung cancers with a durable response, mainly through Arf-p53 pathway-mediated apoptosis and partly through p53-independent inhibition of proliferation.
Article
Medicine, General & Internal
Richard T. Bryan, Sarah J. Pirrie, Ben Abbotts, Shanna Maycock, Vinnie During, Carolyn Lewis, Margaret Grant, Deborah Bird, Adam J. Devall, D. Michael A. Wallace, Nicholas D. James, Lucinda J. Billingham, Maurice P. Zeegers, K. K. Cheng, SELENIB Investigators
Summary: In this multicenter clinical trial, selenium and vitamin E were found to have no significant effect on the risk of recurrence in patients with newly diagnosed non-muscle-invasive bladder cancer (NMIBC). However, vitamin E supplementation was associated with an increased risk of recurrence.
Review
Oncology
Corina Lorz, Marta Oteo, Mirentxu Santos
Summary: Neuroendocrine lung tumors, ranging from benign to malignant types, require effective treatments and early detection systems. The lack of animal models and preclinical models for research is a significant issue in understanding these diseases.
Article
Materials Science, Multidisciplinary
Hang Qian, Dong Wang, Binfeng He, Qian Liu, Yu Xu, Di Wu, Chunfa Chen, Wen Zhang, David Tai Leong, Guansong Wang
Summary: In this study, a strategy was proposed to deliver metformin and siRNA using self-assembled DNA nanostructures. The assembled metformin/DNA nanocomplex exhibited high stability and resistance in physiological conditions and showed a strong synergistic antitumor effect against lung cancer. The research suggests that assembling DNA nanostructures with small molecules is crucial for expanding their applications.
NPG ASIA MATERIALS
(2022)
Article
Oncology
Jens Kohler, Yutong Zhao, Jiaqi Li, Prafulla C. Gokhale, Hong L. Tiv, Aine R. Knott, Margaret K. Wilkens, Kara M. Soroko, Mika Lin, Chiara Ambrogio, Monica Musteanu, Atsuko Ogino, Jihyun Choi, Magda Bahcall, Arrien A. Bertram, Emily S. Chambers, Cloud P. Paweletz, Shripad Bhagwat, Jason R. Manro, Ramon Tiu, Pasi A. Janne
Summary: RAS gene mutations are common oncogenic events in lung cancer, activating various signaling pathways. Targeting ERK1/2 proteins as therapeutic targets shows promise in inhibiting tumor growth and achieving synergistic effects in combination treatments. Future clinical trials are needed to investigate the effectiveness and potential biomarkers for patient stratification in intermittent ERK inhibitor-based treatment schedules.
MOLECULAR CANCER THERAPEUTICS
(2021)
Article
Multidisciplinary Sciences
Rebecca Caeser, Christopher Hulton, Emily Costa, Vidushi Durani, Megan Little, Xiaoping Chen, Sam E. Tischfield, Marina Asher, Faruk Erdem Kombak, Shweta S. Chavan, Nisargbhai S. Shah, Metamia Ciampricotti, Elisa de Stanchina, John T. Poirier, Charles M. Rudin, Triparna Sen
Summary: Activation of the mitogenic signaling pathway plays a significant role in lung cancer, particularly in small cell lung cancer. Research suggests that the most common subtype of SCLC, SCLC-A, is selectively sensitive to MAPK activation, potentially inhibiting proliferation through inducing cell cycle arrest and senescence.